Figure 3.
Validation of miRNA-1827 in age-cardiovascular risk factors-matched non-PAD controls (n = 10) and CLTI (n = 10) patients. miRNA-1827 was validated in a new cohort of patients via qRT-PCR. Compared with miRNA levels in matched control, miRNA-1827 remained significantly increased in CLTI patients (2-folds, p-value < 0.001).